NeoCodex has launched its Hypothesis-Free Clinical Cloning technology for conducting whole-genome association studies. HFCC is “an analysis engine that enables researchers to rapidly analyze millions of SNPs from many individuals to identify specific points of variation in human DNA that underlie particular diseases or determine effects of medicines,” the company said in a statement.
The company claims that HFCC eliminates the need for very large sample sets to achieve statistical significance and that it has been designed to overcome a number of problems associated with WGAS studies, such as epistatic occlusion, aberrant noise signaling, and false marker association.
Genelex has released a new DNA test to determine the proper and safe dosage for Coumadin (warfarin) to within 1.5 mg per day. The test measures two genes — CYP2C9 and VKORC1. The test is available through the company’s website. Patients send in either a blood sample or a cheek swab and receive results within four or five days, the company said.
Genpathway last week launched its Methylated DNA IP-on-Chip assays using Affymetrix GeneChip Tiling Arrays.
The assays include the Methylated DNA IP-on-Chip/Tiling assay, a genome-wide assay using whole-genome tiling arrays; the Methylated DNA IP-on-Chip/Promoter assay for detection of methylated DNA in promoter regions; and the Methylated DNA Query assay for gene-by-gene analysis based on quantitative PCR.
According to Genpathway, the methylation assays, as well as analysis and services, will target pharmaceutical, biotechnology, and academic researchers. The assays could be used in biomarker discovery, drug target identification and validation, compound screening, and patient diagnosis and screening, the company said.